Bernacki RJ - Search Results

1

Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.

Minderman H, Brooks TA, O'Loughlin KL, Ojima I, Bernacki RJ, Baer MR. Minderman H, et al. Among authors: bernacki rj. Cancer Chemother Pharmacol. 2004 May;53(5):363-9. doi: 10.1007/s00280-003-0745-2. Epub 2004 Jan 27. Cancer Chemother Pharmacol. 2004. PMID: 15060738

2

Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.

Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ. Brooks TA, et al. Among authors: bernacki rj. Mol Cancer Ther. 2003 Nov;2(11):1195-205. Mol Cancer Ther. 2003. PMID: 14617793

3

Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators.

Brooks TA, Kennedy DR, Gruol DJ, Ojima I, Baer MR, Bernacki RJ. Brooks TA, et al. Among authors: bernacki rj. Anticancer Res. 2004 Mar-Apr;24(2A):409-15. Anticancer Res. 2004. PMID: 15152938 Free article.

4

The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.

Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR. Brooks TA, et al. Among authors: bernacki rj. Invest New Drugs. 2007 Apr;25(2):115-22. doi: 10.1007/s10637-006-9018-3. Epub 2006 Oct 28. Invest New Drugs. 2007. PMID: 17072745

5

Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.

Ojima I, Borella CP, Wu X, Bounaud PY, Oderda CF, Sturm M, Miller ML, Chakravarty S, Chen J, Huang Q, Pera P, Brooks TA, Baer MR, Bernacki RJ. Ojima I, et al. Among authors: bernacki rj. J Med Chem. 2005 Mar 24;48(6):2218-28. doi: 10.1021/jm049483y. J Med Chem. 2005. PMID: 15771464

6

The use of a novel taxane-based P-glycoprotein inhibitor to identify mutations that alter the interaction of the protein with paclitaxel.

Gruol DJ, Bernd J, Phippard AE, Ojima I, Bernacki RJ. Gruol DJ, et al. Among authors: bernacki rj. Mol Pharmacol. 2001 Jul;60(1):104-13. doi: 10.1124/mol.60.1.104. Mol Pharmacol. 2001. PMID: 11408605

7

Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.

Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki RJ. Vredenburg MR, et al. Among authors: bernacki rj. J Natl Cancer Inst. 2001 Aug 15;93(16):1234-45. doi: 10.1093/jnci/93.16.1234. J Natl Cancer Inst. 2001. PMID: 11504769

8

Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.

Sharma A, Straubinger RM, Ojima I, Bernacki RJ. Sharma A, et al. Among authors: bernacki rj. J Pharm Sci. 1995 Dec;84(12):1400-4. doi: 10.1002/jps.2600841204. J Pharm Sci. 1995. PMID: 8748320

9

Design and synthesis of de novo cytotoxic alkaloids through mimicking taxoid skeleton.

Geng X, Geney R, Pera P, Bernacki RJ, Ojima I. Geng X, et al. Among authors: bernacki rj. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3491-4. doi: 10.1016/j.bmcl.2004.04.060. Bioorg Med Chem Lett. 2004. PMID: 15177459

10

New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells.

Ojima I, Bounaud PY, Takeuchi C, Pera P, Bernacki RJ. Ojima I, et al. Among authors: bernacki rj. Bioorg Med Chem Lett. 1998 Jan 20;8(2):189-94. doi: 10.1016/s0960-894x(97)10218-9. Bioorg Med Chem Lett. 1998. PMID: 9871652

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Search Page

Filters